Skip to content

Study · Systematic review · n = 5,916,559 · 2026

3 results

Semaglutide-Induced Nonarteritic Anterior Ischemic Optic Neuropathy: A Systematic Review and Meta-Analysis.

Khani E, Asham H, Rezabakhsh A, Babaei S, Entezari-Maleki T

Journal of clinical pharmacology1 Aug 2026

PMID42612051 (opens in a new tab)PMCIDPMC13485131 (opens in a new tab)DOI10.1002/jcph.70248 (opens in a new tab)PepBankPUB-42612051
Source linkPubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanSystematic reviewSafety outcome

    In a meta-analysis of eight observational cohorts, semaglutide users had a higher risk of nonarteritic anterior ischemic optic neuropathy than non-semaglutide-treated patients.

    In plain wordsIn pooled observational studies, semaglutide users were linked to a higher risk of a type of optic nerve damage (NAION) than non-users.

    Peptide
    Semaglutide
    Outcome
    IncreaseNAION risk, all studies
    Study

    n = 5,916,559

    Comparator
    Non-semaglutide treatment
    Outcome group
    Adverse events · Eye
    Studied dose
    Dose not stated

    Measurements

    RE
    1.93 ratio
    all studies

    Source sentences

    Summary
    Compared to non-semaglutide-treated patients, semaglutide users had a higher risk of NAION (RE, 1.93; 95% CI, 1.22-3.08; I2, 91%; P  =  .01).
    1 context sentence
    Summary · context
    Eight observational cohort studies, involving a total of 5,916,559 participants, were included in the meta-analysis.
  2. 02HumanSystematic reviewSafety outcome

    In a meta-analysis of observational cohorts, semaglutide use was significantly associated with higher NAION risk in individuals with diabetes.

    In plain wordsIn pooled observational studies, semaglutide use was linked to a higher risk of optic nerve damage (NAION) in people with diabetes.

    Peptide
    Semaglutide
    Outcome
    IncreaseNAION risk in individuals with diabetes
    Study

    n: not reported in source

    Comparator
    Non-semaglutide treatment
    Outcome group
    Adverse events · Eye
    Studied dose
    Dose not stated

    Measurements

    RE
    1.84 ratio
    individuals with diabetes

    Source sentences

    Summary
    There was a significant association between NAION risk and semaglutide use in individuals with diabetes (RE, 1.84; 95% CI, 1.21-2.80; I2, 88.26%; P  < .01).
    1 context sentence
    Summary · context
    Eight observational cohort studies, involving a total of 5,916,559 participants, were included in the meta-analysis.
  3. 03HumanSystematic reviewSafety outcome

    In a meta-analysis of observational cohorts, the association between semaglutide use and NAION risk was not significant among overweight or obese individuals.

    In plain wordsIn pooled observational studies, semaglutide use was not clearly linked to optic nerve damage (NAION) in people with overweight or obesity.

    Peptide
    Semaglutide
    Outcome
    No significant changeNAION risk in overweight or obese individuals
    Study

    n: not reported in source

    Comparator
    Non-semaglutide treatment
    Outcome group
    Adverse events · Eye
    Studied dose
    Dose not stated

    Measurements

    RE
    1.68 ratio
    overweight or obese individuals

    Source sentences

    Summary
    However, the results were non-significant among overweight or obese individuals (RE, 1.68; 95% CI, 0.72-3.91; I2, 83.98%; P  =  .23).
    1 context sentence
    Summary · context
    Eight observational cohort studies, involving a total of 5,916,559 participants, were included in the meta-analysis.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.